Arrowhead (ARWR) Director Michael S. Perry Sells 11,600 Shares

What Happened

• Michael S. Perry, a director of Arrowhead Pharmaceuticals (ARWR), sold 11,600 shares in an open-market transaction on August 18, 2026. The weighted-average sale price reported is $87.30, for a total proceeds of approximately $1,012,680. Footnote 1 states the shares were sold in multiple transactions at prices ranging from $87.20 to $87.44.

Key Details

• Transaction date: 2026-08-18 (reported on Form 4 filed 2026-08-20).
• Transaction type/code: Sale (S) — open market disposal.
• Price: Weighted average $87.30; per-share prices ranged $87.20–$87.44 (see footnote 1).
• Total proceeds: ≈ $1,012,680.
• Shares owned after transaction: Not specified in the provided summary; the filing notes (footnote 2) that reported holdings include previously disclosed RSU-based shares, some of which remain subject to vesting.
• Footnotes: F1 explains the price range and that the reporter can provide a breakdown of shares sold at each price on request; F2 notes inclusion of previously reported RSU-derived shares (some unvested).
• Filing timeliness: Filed two days after the trade (Aug 20, 2026), which appears to be within the typical 2-business-day Form 4 reporting window.

Context

• This was an open-market sale, which is commonly a routine liquidity or portfolio-management transaction; the Form 4 does not disclose a 10b5-1 plan or other reason for the sale. No options were exercised and no gifts or tax-withholding transactions are indicated in the provided details. For full holdings and precise post-sale ownership, consult the complete Form 4 filing (Accession 0001250379-26-000002).